Product News

Rivaroxaban reduces length of hospital stay in patients with symptomatic venous thromboembolism

Simon Nye


The phase III EINSTEIN deep vein thrombosis (DVT) and EINSTEIN pulmonary embolism (PE) trials demonstrated the potential of oral rivaroxaban (Xarelto, Bayer) – 15 mg twice daily for 21 days, followed by 20 mg once daily – for the treatment of venous thromboembolism (VTE), a term that embraces DVT and PE. A subsequent study by van Bellen et al.,[1] published in Current Medical Research and Opinion in 2014, was undertaken to assess the length of initial hospitalisation in patients presenting with either symptomatic DVT or PE using hospitalisation records from these trials.

Author's affiliations

Simon Nye, HMPG

Cite this article

African Journal of Thoracic and Critical Care Medicine 2016;22(4):111. DOI:10.7196/SARJ.2016.v22i4.115

Article History

Date submitted: 2016-12-19
Date published: 2016-12-19

Article Views

Abstract views: 357
Full text views:


  • There are currently no refbacks.

African Journal of Thoracic and Critical Care Medicine| Online ISSN: 2617-0205

This journal is protected by a Creative Commons Attribution - NonCommercial Works License (CC BY-NC 4.0) | Read our privacy policy.

Our Journals: South African Medical Journal | African Journal of Health Professions Education | South African Journal of Bioethics and Law | South African Journal of Child Health | Southern African Journal of Critical Care | African Journal of Thoracic and Critical Care MedicineSouth African Journal of Obstetrics and Gynaecology |